(VIDEO) Drugs for Neglected Diseases Initiative This video is under embargo. Please login to access this video. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Caption Mycetoma is a chronic, destructive morbid inflammatory disease particularly endemic in Sudan as well as in regional neighbors Chad, Niger, Nigeria, Ethiopia, Somalia, parts of Saudi Arabia and Yemen. For many years, the available treatments for mycetoma have only been 25-27 percent effective. However there is hope as DNDi and Japanese pharmaceutical company Eisai Co. Ltd. proceed with the clinical development of Eisai’s anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma. A study will be conducted at the Mycetoma Research Centre to determine the safety and efficacy of the drug. Credit DNDi & Mycetoma Research Centre Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.